GW Pharmaceuticals PLC (NASDAQ:GWPH) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other brokerages have also issued reports on GWPH. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday, August 7th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. BidaskClub raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, TheStreet lowered GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $148.55.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 0.78% during mid-day trading on Friday, hitting $104.99. The stock had a trading volume of 250,428 shares. The firm has a 50 day moving average of $107.46 and a 200-day moving average of $111.45. The stock’s market cap is $2.66 billion. GW Pharmaceuticals PLC has a one year low of $82.93 and a one year high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period in the prior year, the firm earned ($0.05) earnings per share. Equities research analysts expect that GW Pharmaceuticals PLC will post ($6.08) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades GW Pharmaceuticals PLC (GWPH) to “Hold”” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/03/valuengine-upgrades-gw-pharmaceuticals-plc-gwph-to-hold.html.

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in GW Pharmaceuticals PLC by 91.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,157 shares of the biopharmaceutical company’s stock worth $1,228,000 after buying an additional 4,860 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth approximately $304,000. Stevens Capital Management LP acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth approximately $381,000. Parametric Portfolio Associates LLC increased its stake in GW Pharmaceuticals PLC by 21.4% in the first quarter. Parametric Portfolio Associates LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $621,000 after buying an additional 903 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth approximately $230,000. 75.07% of the stock is currently owned by institutional investors.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.